Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Two positive studies for Incyte
June 2020
SHARING OPTIONS:

WILMINGTON, Del.—April saw Incyte report on Phase 3 data from its TRuE-AD program for ruxolitinib cream in patients with mild-to-moderate atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium. The primary endpoint for the Phase 3 TRuE-AD1 and TRuE-AD2 studies was the proportion of patients who achieved Investigator’s Global Assessment (IGA) Treatment Success (IGA-TS), defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline, at Week 8. Both studies met their primary endpoint, with significantly more patients achieving IGA-TS with ruxolitinib compared to a vehicle non-medicated cream. It also had a substantial, sustained effect on itch. Dr. Jim Lee, Incyte’s group vice president, Inflammation & AutoImmunity, said the company plans to submit an NDA for ruxolitinib later this year.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.